does tirzepatide just suppress appetite Tirzepatide: A Breakthrough Approach to Losing Weight Safely What to Know Before Starting

So Is it safe to take Ozempic while breastfeeding

Semaglutide's exact concentration in human milk remains unmeasured, complicating informed decision-making for nursing families

FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease owenhaskins Mar 11, 2024 2 min read The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD)

Adequate hydration (at minimum 64 ounces per day), fiber supplementation, and regular movement help keep things moving